SHMT1 and acute leukemia: Given these observations, it seems that SHMT1/2 and MTHFD2 could be promising targets within the folate metabolism in acute leukemia and encourage combinations between SHMT1/2 or MTHFD2 inhibitors and drugs targeting upstream enzymes such as DHFR.